Skip to main content
SpringerLink
Log in

Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TNFSFS12)

  • Living reference work entry
  • First Online:
Encyclopedia of Signaling Molecules

  • 53 Accesses

Synonyms

APO3L; DR3L; DR3LG; Tnfsf12; Tumor necrosis factor (ligand) superfamily, member 12; Tweak

Historical Background

Tumor necrosis factor superfamily (TNFSF) members are implicated in numerous cellular processes such as proliferation, migration, inflammation, and cell death. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) was first identified as a novel member of the tumor necrosis factor superfamily of proteins displaying pro-apoptotic activity on interferon gamma (INF-γ)-treated human HT-29 colon carcinoma cells (Chicheportiche et al. 1997). The human TWEAK gene is located at chromosomal position 17p13.1 and encodes a 249-amino acid (aa) type II transmembrane-bound protein (mTWEAK). mTWEAK comprises an intracellular N-terminal domain, which contains a potential protein kinase C phosphorylation site, a transmembrane domain, and an extracellular TNF homology domain (THD) containing the receptor-binding site (Chicheportiche et al. 1997) (Fig. 1). mTWEAK is...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Blanco-Colio LM. TWEAK/Fn14 Axis: a promising target for the treatment of cardiovascular diseases. Front Immunol. 2014;5:3.

    Article  PubMed  PubMed Central  Google Scholar 

  • Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:916–22.

    Article  CAS  PubMed  Google Scholar 

  • Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol. 2007;178:8183–94.

    Article  CAS  PubMed  Google Scholar 

  • Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumor-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappa B activation. Biochem J. 2003;371:395–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine. 2007;40:1–16.

    Article  CAS  PubMed  Google Scholar 

  • Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway; an immunological swith for shapping tissue responses. Immunol Rev. 2011;244:99–114.

    Article  CAS  PubMed  Google Scholar 

  • Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272:32401–10.

    Article  CAS  PubMed  Google Scholar 

  • Di Martino L, Dave M, Menghini P, Xin W, Arseneau K, Pizarro T, Cominelli F. Protective role for TWEAK/Fn14 in regulating acute intestinal inflammation and colitis-associated tumorigenesis. Cancer Res. 2016;76:6533–6542.

    Google Scholar 

  • Fernández-Laso V, Sastre C, Valdivielso JM, Betriu A, Fernández E, Egido J, Martín-Ventura JL, Blanco-Colio LM. Soluble TWEAK and major adverse cardiovascular events in patients with CKD. Clin J Am Soc Nephrol. 2016;11:413–22.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, Wajant H. Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14). J Biol Chem. 2012;287:484–95.

    Article  CAS  PubMed  Google Scholar 

  • Jarr KU, Eschricht S, Burkly LC, Preusch M, Katus HA, Frey N, Chorianopoulos E. TNF-like weak inducer of apoptosis aggravates left ventricular dysfunction after myocardial infarction in mice. Mediat Inflamm. 2014;2014:131950.

    Google Scholar 

  • Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198–201.

    Article  CAS  PubMed  Google Scholar 

  • Maecker H, Varfolomeev E, Kischkel F, Lawrence D, Leblanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123:931–44.

    Article  CAS  PubMed  Google Scholar 

  • Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, Bottino D, Zhong H, Roessler M, Vega-Harring SM, Jarutat T, Geho D, Wang K, DeMario M, Goss GD, Schellens JH. Exposure and tumor Fn14 expression as determinants of pharmacodynamics of the anti-TWEAK monoclonal antibody RG7212 in patients with Fn14-positive solid tumors. Clin Cancer Res. 2016;22(4):858–67.

    Article  CAS  PubMed  Google Scholar 

  • Moreno JA, Sastre C, Madrigal-Matute J, Muñoz-García B, Ortega L, Burkly LC, Egido J, Martín-Ventura JL, Blanco-Colio LM. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol. 2013;33:612–20.

    Article  CAS  PubMed  Google Scholar 

  • Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:2061–8.

    Article  PubMed  Google Scholar 

  • Polavarapu R, Gongora MC, Winkles JA, Yepes M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. J Neurosci. 2005;25:10094–100.

    Article  CAS  PubMed  Google Scholar 

  • Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Egido J, Ortiz A. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med. 2009;13:3329–42.

    Article  PubMed  PubMed Central  Google Scholar 

  • Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A. TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant. 2014;29(Suppl 1):i54–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sastre C, Fernández-Laso V, Madrigal-Matute J, Muñoz-García B, Moreno JA, Pastor-Vargas C, Llamas-Granda P, Burkly LC, Egido J, Martín-Ventura JL, Blanco-Colio LM. Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. J Cell Mol Med. 2014;18:721–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tarín C, Fernández-Laso V, Sastre C, Madrigal-Matute J, Gómez M, Zaragoza C, Egido J, Burkly LC, Martín-Ventura JL, Blanco-Colio LM. Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice. J Am Heart Assoc. 2014;3. pii: e000723.

    Google Scholar 

  • Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, Knight B. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology. 2010;52:291–302.

    Article  CAS  PubMed  Google Scholar 

  • Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TP, Smith CA, Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837–46.

    Article  CAS  PubMed  Google Scholar 

  • Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, Burkly LC. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther. 2013;35:1137–49.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular Research Lab, FIIS-Fundación Jiménez Díaz, Av. Reyes Católicos 2, 28040, Madrid, Spain

    Luis M. Blanco-Colio

  2. Biomedical Research Center in Cardiovascular Medicine, CIBERCV, Spain

    Luis M. Blanco-Colio

Authors
  1. Luis M. Blanco-Colio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis M. Blanco-Colio .

Editor information

Editors and Affiliations

  1. Dept. Biological Science, Department of Molecular Science and Tech College of Natural Science, Suwon, Korea (Republic of)

    Sangdun Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media LLC

About this entry

Cite this entry

Blanco-Colio, L.M. (2016). Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TNFSFS12). In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6438-9_101976-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6438-9_101976-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-6438-9

  • Online ISBN: 978-1-4614-6438-9

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation